Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons duringparkinson's disease

Journal of Immunology

Volumn 190, Issue 10, 2013, Pages 5048-5056

  González, Hugo ^a,b   Contreras, Francisco ^a   Prado, Carolina ^a,b   Elgueta, Daniela ^a   Franz, Dafne ^a   Bernales, Sebastián ^a   Pacheco, Rodrigo ^a,c  

^a Fundación Ciencia y Vida   (Chile)

^b UNIVERSIDAD ANDRÉS BELLO   (Chile)

^c UNIVERSIDAD SAN SEBASTIÁN   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 3 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL LOSS; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE TRANSFER; MALE; MICROGLIA; MOUSE; NERVE CELL DEGENERATION; NERVE CELL STIMULATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; T LYMPHOCYTE ACTIVATION; TH1 CELL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; HOMEODOMAIN PROTEINS; INFLAMMATION; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROGLIA; NERVE DEGENERATION; PARKINSON DISEASE; RECEPTORS, DOPAMINE D3; SPLEEN; SUBSTANTIA NIGRA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877819986     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203121     Document Type: Article

References (55)

1. Thomas, B. 2009. Parkinson's disease: from molecular pathways in disease to therapeutic approaches. Antioxid. Redox Signal. 11: 2077-2082.
2. Hirsch, E. C., and S. Hunot. 2009. Neuroinflammation in Parkinson's disease: a target for neuroprotection Lancet Neurol. 8: 382-397.
3. McGeer, P. L., S. Itagaki, H. Akiyama, and E. G. McGeer. 1988. Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 24: 574-576.
4. Kurkowska-Jastrzebska, I., A. Wro-nska, M. Kohutnicka, A. Członkowski, and A. Członkowska. 1999. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 156: 50-61. (Pubitemid 29152982)
5. Benner, E. J., R. Banerjee, A. D. Reynolds, S. Sherman, V. M. Pisarev, V. Tsiperson, C. Nemachek, P. Ciborowski, S. Przedborski, R. L. Mosley, and H. E. Gendelman. 2008. Nitrated a-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS ONE 3: e1376.
6. + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 119: 182-192.
7. Reynolds, A. D., D. K. Stone, J. A. Hutter, E. J. Benner, R. L. Mosley, and H. E. Gendelman. 2010. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J. Immunol. 184: 2261-2271.
8. + T cell subsets. J. Immunol. 182: 4137-4149.
9. Giasson, B. I., J. E. Duda, I. V. Murray, Q. Chen, J. M. Souza, H. I. Hurtig, H. Ischiropoulos, J. Q. Trojanowski, and V. M. Lee. 2000. Oxidative damage linked to neurodegeneration by selective a-synuclein nitration in synucleinopathy lesions. Science 290: 985-989.
10. + regulatory T cells in an animal model of Parkinson's disease. J. Leukoc. Biol. 82: 1083-1094. (Pubitemid 350133504)
11. Pacheco, R., C. E. Prado, M. J. Barrientos, and S. Bernales. 2009. Role of dopamine in the physiology of T-cells and dendritic cells. J. Neuroimmunol. 216: 8-19.
12. Pacheco, R., T. Gallart, C. Lluis, and R. Franco. 2007. Role of glutamate on Tcell mediated immunity. J. Neuroimmunol. 185: 9-19. (Pubitemid 46497434)
13. Pacheco, R., E. Riquelme, and A. M. Kalergis. 2010. Emerging evidence for the role of neurotransmitters in the modulation of T cell responses to cognate ligands. Cent. Nerv. Syst. Agents Med. Chem. 10: 65-83.
14. Franco, R., R. Pacheco, C. Lluis, G. P. Ahern, and P. J. O'Connell. 2007. The emergence of neurotransmitters as immune modulators. Trends Immunol. 28: 400-407. (Pubitemid 47385376)
15. Levite, M. 2008. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr. Opin. Pharmacol. 8: 460-471.
16. Sarkar, C., B. Basu, D. Chakroborty, P. S. Dasgupta, and S. Basu. 2010. The immunoregulatory role of dopamine: an update. Brain Behav. Immun. 24: 525-528.
17. Levite, M. 2012. Dopamine in the immune system: dopamine receptors in immune cells, potent effects, endogenous production and involvement in immune and neuropsychiatric diseases. In Nerve-Driven Immunity. M. Levite, ed. Springer Vienna, Tel Aviv-Yafo, Israel, p. 1-45.
18. Pacheco, R., F. Contreras, and C. Prado. 2012. Cells, molecules and mechanisms involved in the neuro-immune interaction. In Cell Interaction. S. Gowder, ed. InTech Europe, Rijeka, Croatia, p. 139-166.
19. Nakano, K., T. Higashi, K. Hashimoto, R. Takagi, Y. Tanaka, and S. Matsushita. 2008. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem. Biophys. Res. Commun. 373: 286-291.
20. McKenna, F., P. J. McLaughlin, B. J. Lewis, G. C. Sibbring, J. A. Cummerson, D. Bowen-Jones, and R. J. Moots. 2002. Dopamine receptor expression on human T-And B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J. Neuroimmunol. 132: 34-40. (Pubitemid 35333323)
21. Prado, C., F. Contreras, H. González, P. Díaz, D. Elgueta, M. Barrientos, A. A. Herrada, A. Lladser, S. Bernales, and R. Pacheco. 2012. Stimulation of dopamine receptor D5 expressed on dendritic cells potentiates Th17-mediated immunity. J. Immunol. 188: 3062-3070.
22. Besser, M. J., Y. Ganor, and M. Levite. 2005. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFa or both. J. Neuroimmunol. 169: 161-171. (Pubitemid 41528789)
23. + T cells by D1 dopamine receptors: an in vitro analysis. Int. Immunopharmacol. 1: 1363-1374. (Pubitemid 32522988)
24. + T cells in vitro: a receptor-mediated mechanism. Neuroimmunomodulation 9: 23-33. (Pubitemid 32642070)
25. Sarkar, C., S. Das, D. Chakroborty, U. R. Chowdhury, B. Basu, P. S. Dasgupta, and S. Basu. 2006. Cutting Edge: stimulation of dopamine D4 receptors induce T cell quiescence by up-regulating Kruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation. J. Immunol. 177: 7525-7529. (Pubitemid 44846267)
26. + T cells via dopamine receptor D3. J. Immunol. 176: 848-856. (Pubitemid 43099681)
27. Nakano, K., T. Higashi, R. Takagi, K. Hashimoto, Y. Tanaka, and S. Matsushita. 2009. Dopamine released by dendritic cells polarizes Th2 differentiation. Int. Immunol. 21: 645-654.
28. Santambrogio, L., M. Lipartiti, A. Bruni, and R. Dal Toso. 1993. Dopamine receptors on human T-And B-lymphocytes. J. Neuroimmunol. 45: 113-119.
29. Levite, M., Y. Chowers, Y. Ganor, M. Besser, R. Hershkovits, and L. Cahalon. 2001. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates b1 integrin function. Eur. J. Immunol. 31: 3504-3512. (Pubitemid 34030963)
30. Tsao, C. W., Y. S. Lin, and J. T. Cheng. 1997. Effect of dopamine on immune cell proliferation in mice. Life Sci. 61: PL 361-371.
31. + regulatory T-cell activity: implications for neurodegeneration. J. Neurosci. 24: 6133-6143. (Pubitemid 38891104)
32. + regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 109: 632-642. (Pubitemid 46105964)
33. Ilani, T., R. D. Strous, and S. Fuchs. 2004. Dopaminergic regulation of immune cells via D3 dopamine receptor: a pathway mediated by activated T cells. FASEB J. 18: 1600-1602. (Pubitemid 39561646)
34. Nagai, Y., S. Ueno, Y. Saeki, F. Soga, M. Hirano, and T. Yanagihara. 1996. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology 46: 791-795. (Pubitemid 26099651)
35. Barcia, C., C. M. Ros, V. Annese, A. Go'mez, F. Ros-Bernal, D. Aguado-Llera, M. E. Martínez-Pagán, V. de Pablos, E. Fernandez-Villalba, and M. T. Herrero. 2012. IFN-g signaling, with the synergistic contribution of TNF-A, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Dis. 3: e379.
36. Joseph, J. D., Y. M.Wang, P. R. Miles, E. A. Budygin, R. Picetti, R. R. Gainetdinov, M. G. Caron, and R. M. Wightman. 2002. Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience 112: 39-49. (Pubitemid 34603496)
37. Benner, E. J., R. L. Mosley, C. J. Destache, T. B. Lewis, V. Jackson-Lewis, S. Gorantla, C. Nemachek, S. R. Green, S. Przedborski, and H. E. Gendelman. 2004. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 101: 9435-9440. (Pubitemid 38812892)
38. + T cells mediate cytotoxicity in neurodegenerative diseases. J. Clin. Invest. 119: 13-15.
39. Lucin, K. M., and T. Wyss-Coray. 2009. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 64: 110-122.
40. Barbanti, P., G. Fabbrini, A. Ricci, G. Bruno, R. Cerbo, E. Bronzetti, F. Amenta, and G. Luigi Lenzi. 2000. Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease. Mech. Ageing Dev. 120: 65-75.
41. Ricci, A., E. Bronzetti, L. Felici, S. Greco, and F. Amenta. 1998. Labeling of dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes with [3H]7-OH-DPAT: a combined radioligand binding assay and immunochemical study. J. Neuroimmunol. 92: 191-195. (Pubitemid 29016004)
42. Ricci, A., E. Bronzetti, F. Mignini, S. K. Tayebati, D. Zaccheo, and F. Amenta. 1999. Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes. J. Neuroimmunol. 96: 234-240. (Pubitemid 29234498)
43. Basu, S., and P. S. Dasgupta. 2000. Dopamine, a neurotransmitter, influences the immune system. J. Neuroimmunol. 102: 113-124.
44. Barbanti, P., E. Bronzetti, A. Ricci, R. Cerbo, G. Fabbrini, M. G. Buzzi, F. Amenta, and G. L. Lenzi. 1996. Increased density of dopamine D5 receptor in peripheral blood lymphocytes of migraineurs: a marker for migraine? Neurosci. Lett. 207: 73-76. (Pubitemid 26116541)
45. Blesa, J., S. Phani, V. Jackson-Lewis, and S. Przedborski. 2012. Classic and new animal models of Parkinson's disease. J. Biomed. Biotechnol. 2012: 845618.
46. Joyce, J. N., C. Woolsey, H. Ryoo, S. Borwege, and D. Hagner. 2004. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor. BMC Biol. 2: 22.
47. Kelley, B. J., A. P. Duker, and P. Chiu. 2012. Dopamine agonists and pathologic behaviors. Parkinsons Dis. 2012: 603631.
48. Hirsch, E. C., S. Vyas, and S. Hunot. 2012. Neuroinflammation in Parkinson's disease. Parkinsonism Relat. Disord. 18(Suppl. 1): S210-S212.
49. Barnum, C. J., and M. G. Tansey. 2010. Modeling neuroinflammatory pathogenesis of Parkinson's disease. Prog. Brain Res. 184: 113-132.
50. Kurkowska-Jastrzebska, I., A. Wro-nska, M. Kohutnicka, A. Członkowski, and A. Członkowska. 1999. MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. Acta Neurobiol. Exp. 59: 1-8. (Pubitemid 29100019)
51. Wu, W. L., D. A. Burnett, R. Spring, W. J. Greenlee, M. Smith, L. Favreau, A. Fawzi, H. Zhang, and J. E. Lachowicz. 2005. Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. J. Med. Chem. 48: 680-693. (Pubitemid 40209091)
52. Strange, P. G. 2001. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol. Rev. 53: 119-133. (Pubitemid 32173111)
53. Sunahara, R. K., H. C. Guan, B. F. O'Dowd, P. Seeman, L. G. Laurier, G. Ng, S. R. George, J. Torchia, H. H. Van Tol, and H. B. Niznik. 1991. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350: 614-619. (Pubitemid 21912283)
54. Malmberg, A., D. M. Jackson, A. Eriksson, and N. Mohell. 1993. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol. Pharmacol. 43: 749-754. (Pubitemid 23146274)
55. Bo, L., S. Mork, P. A. Kong, H. Nyland, C. A. Pardo, and B. D. Trapp. 1994. Detection of MHC class II-Antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J. Neuroimmunol. 51: 135-146. (Pubitemid 24147480)